Reapplix
Reapplix A/S is a Danish medtech company that has developed the 3C Patch System, an autologous blood-derived wound patch for treating hard-to-heal diabetic foot ulcers. It sells the device and consumables to US and European hospitals and wound care clinics under Medicare reimbursement, following FDA 510(k) clearance and Medicare National Coverage Determination.
- Company typePrivate
- Founded2008
- HeadquartersBirkerød, Denmark
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Reapplix does
Reapplix A/S is a Danish regenerative medicine company founded in 2008 and headquartered in Birkerød, Denmark, with a US subsidiary (Reapplix Inc) established in Texas in 2018 to drive commercialization in North America. The company has developed the 3C Patch System, an autologous, multi-layered wound therapy that uses a small sample of a patient's own blood and processes it through a proprietary three-step centrifugation, coagulation, and compaction workflow to produce a solid patch containing leukocytes, platelets, fibrin, and growth factors, applied directly to the wound at the point of care in approximately 20 minutes. The primary indication is hard-to-heal diabetic foot ulcers, where the product is clinically validated by a 269-patient randomized controlled trial published in The Lancet Diabetes & Endocrinology (2018) and recommended in IWGDF guidelines.
Reapplix generates revenue by selling the 3C Patch Centrifuge device and consumables to hospitals, outpatient wound care clinics, and diabetic foot centers, with the underlying treatment billable to Medicare at approximately USD 1,715-1,759 per patient visit (effective January 2022) under a final National Coverage Determination issued in April 2021. Go-to-market is enterprise field sales-led in both the US and Europe, supplemented by GPO contracts with Vizient (May 2023) and Premier Inc (April 2026), which together cover the majority of US hospital purchasing volume. The company holds FDA 510(k) clearances (2016 and 2017), CE Mark, and a portfolio of granted patents spanning the US, Europe, Japan, China, Canada, and Eurasia.
The investor base is anchored by Danish institutional and life science investors including Novo Seeds (the early-stage arm of Novo Holdings/Novo Nordisk Foundation), SEED Capital, Vækstfonden, Lauxera Capital Partners, MK Ventures, and North-East Healthcare, with total disclosed equity funding of approximately USD 31.6 million across rounds from 2009 through 2020, the largest being a USD 22.6 million raise in July 2020 specifically earmarked for US commercialization. Reapplix remains a privately held company with 11-50 employees and does not publicly disclose revenue.
Reapplix firmographics
Firmographics- Name
- Reapplix
- Legal name
- Reapplix A/S
- Website
- https://reapplix.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Reapplix A/S is a Danish medtech company that has developed the 3C Patch System, an autologous blood-derived wound patch for treating hard-to-heal diabetic foot ulcers. It sells the device and consumables to US and European hospitals and wound care clinics under Medicare reimbursement, following FDA 510(k) clearance and Medicare National Coverage Determination.
- Ownership category
- akta.pro rank
Reapplix industry classification
Industry- Product category
- Advanced Wound Care Medical Devices
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)
- akta.pro secondary industry
- Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG)
Keywords
Where Reapplix is headquartered
LocationHeadquarters
- HQ city
- Birkerød
- HQ country
- Denmark
- HQ region
- Europe
Offices3 records
Markets served
Reapplix business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales
Revenue model
- 3C Patch Product Sales: Sale of 3C Patch System and related products to healthcare providers for treatment of diabetic foot ulcers. Revenue generated from hospital outpatient departments and wound care clinics purchasing the patch system and centrifuge devices.
- Medicare Reimbursement: Medicare reimbursement for 3C Patch therapy at approximately USD 1,622.74 - USD 1,759 per patient treatment visit, covering treatment of chronic non-healing diabetic wounds for up to 20 weeks.
- Clinical Services: Point-of-care treatment services where the 3C Patch is applied directly to wounds at healthcare facilities.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Transaction based/ take rate | Pay-as-you-go | Medicare reimbursement rate for 3C Patch therapy |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels5 records
Reapplix product offering
Product offeringCore offering
Reapplix develops and sells the 3C Patch® System, an autologous medical device that processes a small sample of a patient's own blood into a multi-layered leukocyte, platelet, and fibrin patch for treating hard-to-heal diabetic foot ulcers. The system includes the 3C Patch Centrifuge with optical sensors and produces a therapeutic patch at point-of-care in approximately 20 minutes without any reagents or additives.
Product overview
Reapplix offers a unified medical device product portfolio centered on the 3C Patch® System, an autologous wound therapy solution. The core offering consists of the 3C Patch® (a multi-layered leukocyte, platelet, and fibrin patch derived from the patient's own blood) and the 3C Patch System® (which includes the automated 3C Patch Centrifuge). The system works by drawing a small blood sample from the patient, processing it through centrifugation to separate, coagulate and compact blood components into a therapeutic patch, which is then applied directly to the wound at point-of-care. The product requires no reagents or additives and is designed for use in treating hard-to-heal diabetic foot ulcers, with clinical evidence supporting accelerated wound healing.
Differentiator
Problem solved
Functional benefit
Brands
- 3C Patch: Autologous multi-layered blood-based wound management system for diabetic foot ulcers, made entirely from the patient's own blood without reagents or additives. Takes about 20 minutes to produce at point-of-care and is clinically proven to accelerate wound healing.
Products and services
- 3C Patch® System The 3C Patch® System is a complete autologous wound management medical device that separates, coagulates, and compacts a small sample of a patient's own blood into a solid multi-layered leukocyte, platelet, fibrin, and growth factor patch applied directly to hard-to-heal diabetic foot ulcers at point-of-care in approximately 20 minutes. Sold to hospital outpatient departments, wound care centers, and diabetes foot clinics in the US and Europe.
Quantifiable outcome
- 58% increased chance of wound healing (Odds Ratio 1.58, p=0.0235)
- +4 more outcomes
Companies that use Reapplix
Customer profileNamed customers3 records
Segments1 record
Ideal customer profiles1 record
Reapplix technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Reapplix partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- Premier InccoreLeading technology-driven healthcare improvement company. Awarded Reapplix Technology Breakthrough designation for 3C Patch Wound Management System in April 2026. Provides access to Premier member healthcare organizations with special pricing terms.
- Vizient InccoreNation's largest member-driven healthcare performance improvement company. Awarded Innovative Technology contract for 3C Patch Wound Management System in May 2023. Represents more than $130 billion in annual purchasing volume.
- Nottingham University Hospitals NHS TrustcoreIndependent sponsor of the large LeucoPatch/3C Patch randomized controlled trial (ClinicalTrials.gov NCT02224742). Trial conducted at 32 hospitals and wound centers in UK, Denmark and Sweden.
Scale indicators6 records
Recent moves8 records
Expansion highlights6 records
Reapplix competitors and assessment
Company assessmentMarket position
Strengths4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Reapplix social profiles
Digital presenceReapplix compliance and trust
Trust signalCompliance8 records
Reapplix financial estimates
Financial estimateRevenue estimate
Valuation estimate
Reapplix leadership team
Management profileNumber of profiles
Profiles11 records
Reapplix subsidiaries and ownership
Company hierarchySubsidiaries1 record
Reapplix funding detail
Funding detailFunding overview
Funding rounds6 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Reapplix M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Reapplix
What does Reapplix do?
Reapplix develops and sells the 3C Patch® System, an autologous medical device that processes a small sample of a patient's own blood into a multi-layered leukocyte, platelet, and fibrin patch for treating hard-to-heal diabetic foot ulcers. The system includes the 3C Patch Centrifuge with optical sensors and produces a therapeutic patch at point-of-care in approximately 20 minutes without any reagents or additives.
Is Reapplix a public or private company?
Reapplix is a private company. It is classified as venture growth investor backed and is currently operating.
When was Reapplix founded?
Reapplix was founded in 2008. It employs 11 to 50 people.
Where is Reapplix based?
Reapplix is headquartered in Birkerød, Denmark, in the Europe region.
How does Reapplix make money?
Three revenue lines are on record. 3C Patch Product Sales are the primary driver. The others are medicare Reimbursement and clinical Services.
Does Reapplix have an API?
No public API is recorded for Reapplix.
What industry is Reapplix in?
Reapplix's product category is Advanced Wound Care Medical Devices. Its primary akta.pro industry code is HLAHALAE, Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts), with a secondary code of HLAAAGAG, Wound Healing & Skin Regeneration (advanced dressings, skin substitutes). Its NAICS code is 339113 and its SIC code is 3841.